Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
Understanding the distinction between direct medication effects and indirect consequences of weight loss is essential for patients and clinicians navigating treatment decisions during reproductive years
These medications, except exenatide, are safe for patients with mild to severe renal impairment without dose adjustments (73, 74)
If additional glycemic control is needed after at least 4 weeks on the: 0.5 mg dosage, the dosage may be increased to 1 mg once weekly
Ventricular tachycardia (VT), though rare, is the most dangerous arrhythmia associated with GLP-1 use in patients with underlying structural heart disease
Dziaania niepodane wystpuj czciej na pocztku titracji i zazwyczaj s przemijajce oraz agodne do umiarkowanych